(R) Fesoterodine

(R) Fesoterodine Struktur
286930-02-7
CAS-Nr.
286930-02-7
Englisch Name:
(R) Fesoterodine
Synonyma:
PF-00695838;Fesoterodine;Unii-621G617227;(R) Fesoterodine;2-Methylpropionic acid 2-[3-(N,N-diisopropylamino)-1(R)-phen...;(R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl isobutyrate;2-Methylpropanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester;Propanoic Acid 2-Methyl- 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl Ester;Desfesoterodine,Fesoterodine,OAB,muscarinic,overactive,Inhibitor,SPM7605,mAChR,orally,5-HMT,antimuscarinic,bladder,Muscarinic acetylcholine receptor,inhibit,receptor
CBNumber:
CB61175365
Summenformel:
C26H37NO3
Molgewicht:
411.58
MOL-Datei:
286930-02-7.mol

(R) Fesoterodine Eigenschaften

Dichte
1.043
storage temp. 
Store at -20°C,unstable in solution, ready to use.
Löslichkeit
Ethanol: 100 mg/mL (242.97 mM)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitsschädlich bei Verschlucken. Akute Toxizität oral Kategorie 4 Warnung P264, P270, P301+P312, P330, P501
H315 Verursacht Hautreizungen. Hautreizung Kategorie 2 Warnung P264, P280, P302+P352, P321,P332+P313, P362
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung P264, P280, P305+P351+P338,P337+P313P
H335 Kann die Atemwege reizen. Spezifische Zielorgan-Toxizität (einmalige Exposition) Kategorie 3 (Atemwegsreizung) Warnung
Sicherheit
P261 Einatmen von Staub vermeiden.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P301+P312 BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.
P302+P352 BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

(R) Fesoterodine Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Fesoterodine, launched for the treatment of OAB, is an orally active pro-drug that is converted in vivo to its active metabolite 5-HMT through hydrolysis by non-specific esterases. 5-HMT is also an active metabolite of tolterodine (Detrol), which has been marketed for the treatment of OAB since 1998. 5-HMT is a potent muscarinic antagonist, with essentially equivalent affinity for M1, M2, M3, M4, and M5 receptors (Ki=0.32, 0.63, 1.26, 2, and 0.63 nM, respectively). The binding of 5-HMT is stereoselective; the corresponding S-enantiomer has at least 100 times lower binding affinity for all five receptors. Fesoterodine is supplied as its fumarate salt in an extended release tablet form. The recommended starting dose is 4 mg once daily. On the basis of individual response and tolerability, the dose may be increased to 8 mg once daily. Following oral administration, fesoterodine is not detected in the peripheral blood, thereby indicating a rapid and complete bioconversion to 5-HMT. Bioavailability of 5-HMT is about 52%. After single- or multiple-dose oral administration of fesoterodine in doses from 4 to 28 mg, plasma concentrations of 5-HMT are proportional to the dose. Maximum plasma levels are reached after approximately 5 h. No accumulation occurs after multiple-dose administration. 5-HMT is further metabolized in the liver through oxidation of the hydroxymethyl group and oxidative cleavage of N-alkyl groups mediated by CYP2D6 and CYP3A4. 5-HMT and its metabolites are primarily eliminated through renal excretion.
The most common adverse events associated with fesoterodine include dry mouth, constipation, and dyspepsia. Fesoterodine is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.

(R) Fesoterodine Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


(R) Fesoterodine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 47)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29914 58
Chongqing Chemdad Co., Ltd
+86-023-61398051 +8613650506873
sales@chemdad.com China 39916 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 47465 58
Neostar United (Changzhou) Industrial Co., Ltd.
+86-519-519-85557386
marketing1@neostarunited.com China 8349 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 29831 58
changzhou huayang technology co., ltd
+8615250961469
2571773637@qq.com China 9821 58
Hefei TNJ Chemical Industry Co.,Ltd.
0551-65418684 +8618949823763
sales@tnjchem.com China 25363 58
TargetMol Chemicals Inc.
+1-781-999-5354
support@targetmol.com United States 19973 58
GIHI CHEMICALS CO.,LIMITED
+8618058761490
info@gihichemicals.com China 50001 58
Changzhou AniKare Pharmatech Co., Ltd.
+86-0519-8359-8696 +8618018249389
sales@anikare.com China 6436 58

  • (R) Fesoterodine
  • Propanoic Acid 2-Methyl- 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl Ester
  • 2-Methylpropanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester
  • Fesoterodine
  • Unii-621G617227
  • (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl isobutyrate
  • PF-00695838
  • 2-Methylpropionic acid 2-[3-(N,N-diisopropylamino)-1(R)-phen...
  • Desfesoterodine,Fesoterodine,OAB,muscarinic,overactive,Inhibitor,SPM7605,mAChR,orally,5-HMT,antimuscarinic,bladder,Muscarinic acetylcholine receptor,inhibit,receptor
  • 286930-02-7
  • 266930-03-8
Copyright 2019 © ChemicalBook. All rights reserved